NeuroCog Trials, Inc. announces that it has grown to 100 full time employees. Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, said, “The mission of NeuroCog has always been to provide high quality cognitive methodologies for our sponsors and the patients whom they aim to help. We have never
set a number on what size we want to be. We have just worked relentlessly to develop and maintain techniques that will enhance reliability and sensitivity of cognitive outcomes in clinical trials. We feel that this growth is a testament to the vision that we share with our academic, government, and industry colleagues. We all want the same thing: better treatments for those who suffer. We are honored that we have been chosen to be a partner to help meet this challenge.”
NeuroCog Trials, Inc. has received contracts to conduct trials in schizophrenia, major depression, bipolar disorder, Alzheimer’s Disease, Mild Cognitive Impairment, brain cancer, liver disease, and Restless Legs Syndrome, among others. Dr. Keefe added, “cognition is increasingly being recognized as a key component of everyday life in many different disorders. Successful treatment of cognitive impairment will have a beneficial impact on a variety of aspects of everyday functioning and are key outcome measures in clinical trials. The growth of our company not only reflects our reputation for being reliable and responsive, but also that the pharmaceutical industry has a strong ongoing need for cognitive data that are reliable and responsive. We are gratified to be at the center of this effort.”